Valneva 6-K Packs Shigella Phase 2 Win and 94% Five-Year Chikungunya Persistence
VALN sits 23% above its 52-week low of $4.75.
Summary
Valneva filed a 6-K with two press releases: positive Phase 2 results for its tetravalent Shigella vaccine S4V2 (CHIM primary endpoint met, infant immunogenicity positive) and five-year IXCHIQ data showing 94% of 221 adults still seroresponsive after a single dose.
Key Events · Product Development and Regulatory · VALN
-
Shigella CHIM Trial Meets Primary Endpoint
In the ~120-subject US CHIM trial S4V03, S4V2 produced a statistically significant reduction in shigellosis from the S. sonnei serotype versus placebo after challenge with the 53G strain.
-
Infant Immunogenicity Positive Across Four Serotypes
The 110-infant Kenya trial S4V02 showed statistically significant anti-LPS IgG increases for all four targeted Shigella serotypes versus control, with titers above baseline six months later; the company says dose and schedule still need optimization.
-
No Phase 3 Path or Cost Disclosed
Valneva is evaluating the complete Phase 2 datasets to determine the path forward for S4V2, which holds FDA Fast Track designation granted in 2024; LimmaTech sponsored both trials and the Gates Foundation funded the infant study.
-
IXCHIQ Holds 94% Seroresponse at Five Years
94% of 221 evaluable healthy adults kept neutralizing antibody titers above the ≥150 µPRNT50 threshold five years after a single dose, with comparable GMTs and seroresponse rates in adults 65 and older.
Analysis · VALN · Life Sciences
Two clinical readouts land in one filing. The Shigella S4V2 programme met its CHIM primary endpoint with a statistically significant reduction in S. sonnei shigellosis versus placebo, and infant immunogenicity showed significant anti-LPS IgG rises across all four serotypes — but management is still assessing the full datasets before committing to a Phase 3 design, so no timeline or cost is disclosed. The IXCHIQ five-year data (94% seroresponse in 221 evaluable adults, holding up in the 65+ group) defends the durability story for the marketed chikungunya vaccine at a time when its UK authorization was revoked in October 2026. Neither release carries revenue, guidance or financing terms, so the move hinges on how much credibility the market gives the Shigella path forward.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VALN was trading at $5.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $553.5M. The 52-week trading range was $4.75 to $12.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.